过度活性膀的病理生理学和药物治疗,包括β3-腺素受体激活剂 - 基本研究前景
Joonbeom Kwon1,2, Duk Yoon Kim3, Kang Jun Cho1,4
1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
International neurourology journal
|March 10, 2024
概括
过度活性膀 (OAB) 涉及紧迫性和频率. 目前的治疗方法,如抗肌肉类药物具有有限的效果,而β3-上腺体受体激动剂在通过向神经信号通路来管理OAB方面表现有前途.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 过度活性膀 (OAB) 是一种综合症,其特点是尿急,频率和夜尿,具有各种潜在病理.
- 目前对OAB产生的假设包括神经性,肌性和泌尿器官机制.
- 在膀填充期间,自主肌源性收缩和 afferent 信号可能会导致紧迫性.
研究的目的:
- 探索OAB生成的机制和不同药物类别的治疗效果.
- 为了比较抗糖药和β3-上腺素受体 (AR) 激动剂在OAB治疗中的疗效.
- 阐明β3-AR激动剂的特定作用,如mirabegron和vibegron,在神经信号和泌尿道上.
主要方法:
- 对OAB病理生理学现有假设和研究的审查.
- 对抗肌肉类药物和β3-AR激动剂的作用机制的分析.
- 检查临床前模型,包括膀输出阻塞 (BOO) 诱导的虫过度活动.
主要成果:
- 抗肌肉性药物主要阻断 afferent神经传输,而不是在治疗剂量直接放松detrusor光滑肌肉.
- β3-AR激动剂抑制了附属信号,在正常和病理条件下向不同的纤维类型.
- 米拉贝格朗和维贝格朗在预防乙胆释放和调节尿路细胞信号传递方面表现出潜在的潜力.
结论:
- β3-AR激动剂通过向异位和异位通路,为OAB提供了一个有前途的治疗途径.
- 了解不同的作用机制对于优化OAB治疗策略至关重要.
- 对尿路β3-AR通路的进一步研究可能会为OAB揭示新的治疗点.
相关概念视频
Adrenergic Agonists: Therapeutic Classification
785
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
785
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
807
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
807
Antihypertensive Drugs: Action of β1 Blockers
447
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
447
Adrenergic Agonists: Therapeutic Uses
774
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
774
Adrenergic Agonists: Direct-Acting Agents
1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.5K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
801
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
801


